BioCentury | Jul 2, 2020
Finance

SK becomes Korea’s third-largest public healthcare company after $800M IPO

Neurology company SK more than doubled its value to $8 billion on its first day of trading Thursday after raising just under $800 million in the largest biotech IPO in Korea so far this year....
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

Takeda receives $120M up front for seven neurology therapies  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) an exclusive, worldwide license to seven neurology programs: three mood disorder therapies that have completed...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

Immunology, inflammation and oncology company Gossamer Bio Inc. (NASDAQ:GOSS) said CMO Jakob Dupont has stepped down. CEO Sheila Gujrathi will take on the role’s responsibilities; the biotech told BioCentury there are no plans to immediately...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

FDA approves Pear’s cognitive behavioral insomnia therapy  FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia. The prescription digital therapeutic is the first to be approved via simultaneous review under the standard 510(k)...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Olivier Brandicourt will join its board. Brandicourt, who retired as CEO of Sanofi (Euronext:SAN; NASDAQ:SNY) last year, also plans to join Blackstone Group as a senior adviser....
BioCentury | Feb 18, 2020
Regulation

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

FDA is reviewing a pair of candidates to treat lung cancer and hereditary angioedema, while the European Commission has approved a new competitor for Eylea in wet AMD and expanded another drug's label to treat...
BC Extra | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said co-founder C. Frank Bennett will become CSO, with Eric Swayze succeeding him as SVP of research. Bennett will remain the antisense oligonucleotide company’s franchise leader for neurology drug discovery. Swayze...
Items per page:
1 - 10 of 501
BioCentury | Jul 2, 2020
Finance

SK becomes Korea’s third-largest public healthcare company after $800M IPO

Neurology company SK more than doubled its value to $8 billion on its first day of trading Thursday after raising just under $800 million in the largest biotech IPO in Korea so far this year....
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

Takeda receives $120M up front for seven neurology therapies  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) an exclusive, worldwide license to seven neurology programs: three mood disorder therapies that have completed...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

Immunology, inflammation and oncology company Gossamer Bio Inc. (NASDAQ:GOSS) said CMO Jakob Dupont has stepped down. CEO Sheila Gujrathi will take on the role’s responsibilities; the biotech told BioCentury there are no plans to immediately...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

FDA approves Pear’s cognitive behavioral insomnia therapy  FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia. The prescription digital therapeutic is the first to be approved via simultaneous review under the standard 510(k)...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Olivier Brandicourt will join its board. Brandicourt, who retired as CEO of Sanofi (Euronext:SAN; NASDAQ:SNY) last year, also plans to join Blackstone Group as a senior adviser....
BioCentury | Feb 18, 2020
Regulation

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

FDA is reviewing a pair of candidates to treat lung cancer and hereditary angioedema, while the European Commission has approved a new competitor for Eylea in wet AMD and expanded another drug's label to treat...
BC Extra | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said co-founder C. Frank Bennett will become CSO, with Eric Swayze succeeding him as SVP of research. Bennett will remain the antisense oligonucleotide company’s franchise leader for neurology drug discovery. Swayze...
Items per page:
1 - 10 of 501